Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RNA
ATRIUM THERAPEUTICS, INC.
NASDAQ
$13.64
▼ DOWN 2.43% (-0.34)

KEY STATISTICS

Market Cap$233.32 M
52w High$16.77
52w Low$11.13
Dividend Yield—
Frequency—
P/E-8.63
Volume108.64K
Shares Out.17.11M

COMPANY

LEADERSHIP

Kathleen Gallagher
CHIEF EXECUTIVE
Kathleen Gallagher

COMPENSATION 2026

Salary$659,900
Stock Awards$10,748,480
Incentive Plan Pay$594,000
All Other Comp.$17,010
Total$14,176,480

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 27, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
511

PRICE TARGET

Target High$25.00
Target Low$25.00
Target Median$25.00
Target Consensus$25.00

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$15.00M
NOV
12
THU

PRICE

$13.64 ▼ DOWN 2.43% (−$0.34)
$13.50$13.65$13.80$13.959:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM13.64

About Atrium Therapeutics, Inc.

http://www.atriumtherapeutics.com ↗

Avidity Biosciences develops antibody oligonucleotide conjugates for serious diseases, with lead candidates targeting myotonic dystrophy, Duchenne Muscular Dystrophy, and facioscapulohumeral muscular dystrophy, plus Pompe disease therapy.

INDUSTRY

Biotechnology

A PRODUCT ATRIUM THERAPEUTICS, INC. IS KNOWN FOR

Delpacibart etedesiran (AOC 1001)
Delpacibart etedesiran (AOC 1001)

Delpacibart etedesiran, Avidity Biosciences' lead AOC candidate for myotonic dystrophy type 1, is a late-stage, FDA-designated Breakthrough Therapy targeting the disease's genetic root with a novel antibody-siRNA approach.

COMPETITORS

COMPETITOR
ALNY COMPARE
ARWR COMPARE
DYN COMPARE
IONS COMPARE
SRPT COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
67
LISTED HERE
15
RANKED BY POSITION SIZE
VTI
0.00% · 518.4K
XSU.TO
0.01% · 372.5K
SCHA
0.00% · 75.9K
R2US.L
0.01% · 35.2K
XRS2.F
0.01% · 13.4K
FESM
0.00% · 12.7K
MOON
2.33% · 10.3K
RSSL
0.01% · 6.8K
AVUS
0.00% · 5.7K
MNTL
1.88% · 5.4K
OMFS
0.02% · 4.4K
URTY
0.00% · 584
EVNT
0.05% · 338
STXG
0.00% · 44
RESM
0.01% · 34

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
467
TOP 12 OF 467 · RANKED BY POSITION SIZE
Fmr LLC
21.6M sh · $940.5M
Janus Henderson Group Plc
14.5M sh · $632.81M
Vanguard Group Inc
13.6M sh · $984.52M
Blackrock, Inc.
12.9M sh · $926.93M
Rtw Investments, LP
11.4M sh · $495.51M
Wellington Management Group Llp
10.1M sh · $438.54M
Price T Rowe Associates Inc /Md/
9.8M sh · $426.44M
Ra Capital Management, L.P.
8.6M sh · $623.28M
Blackrock Inc.
8.6M sh · $352.23M
Avoro Capital Advisors LLC
7.6M sh · $333.09M
Balyasny Asset Management L.P.
6.0M sh · $435.71M
Pentwater Capital Management LP
6.0M sh · $434.69M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR
LEVIN ARTHUR A
Sale · 1.8K shares
2026-01-21
★
OFFICER: CHIEF HUMAN RESOURCES OFFICER
McCarthy Teresa
Sale · 1.5K shares
2026-01-21
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Flanagan W. Michael
Sale · 2.6K shares
2026-01-21
★
OFFICER: CHIEF FINANCIAL OFFICER
MacLean Michael F
Sale · 1.8K shares
2026-01-21

MOST RECENT ANALYST GRADES

GRADE SUMMARY
MARKET PERFORM 3
BUY 2
NEUTRAL 2
HOLD 2
SECTOR PERFORM 1
OUTPERFORM 1
11 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Chardan Capital NEUTRAL TD Cowen HOLD RBC Capital SECTOR PERFORM Raymond James MARKET PERFORM Bernstein MARKET PERFORM Citigroup NEUTRAL Leerink Partners MARKET PERFORM

SECTORS PEERS

PEERPRICE
MRNA$55.81COMPARE
JAZZ$184.18COMPARE
MDGL$446.27COMPARE
ABVX$126.43COMPARE
TECH$50.96COMPARE
CYTK$62.23COMPARE
RYTM$89.07COMPARE
CAI$18.82COMPARE